These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28052221)

  • 61. [Bone quality].
    Ito M
    Nihon Rinsho; 2009 May; 67(5):921-5. PubMed ID: 19432110
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Osteodensitometry and duration of treatment in osteoporosis].
    Bartl R
    Dtsch Med Wochenschr; 2010 Mar; 135(11):534. PubMed ID: 20221972
    [No Abstract]   [Full Text] [Related]  

  • 63. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.
    Lin T; Wang C; Cai XZ; Zhao X; Shi MM; Ying ZM; Yuan FZ; Guo C; Yan SG
    Int J Clin Pract; 2012 Apr; 66(4):399-408. PubMed ID: 22313934
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Alendronate treatment in osteogenesis imperfecta.
    Madenci E; Yilmaz K; Yilmaz M; Coskun Y
    J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
    Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
    Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
    Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210
    [TBL] [Abstract][Full Text] [Related]  

  • 67. NOFSA statement on generic bisphosphonates.
    Hough S
    S Afr Med J; 2006 Sep; 96(9):758-60. PubMed ID: 17068638
    [No Abstract]   [Full Text] [Related]  

  • 68. Bisphosphonate therapy in polyostotic fibrous dysplasia.
    Kumar S
    Indian Pediatr; 2004 Oct; 41(10):1069-70. PubMed ID: 15523142
    [No Abstract]   [Full Text] [Related]  

  • 69. Anabolic therapy in glucocorticoid-induced osteoporosis.
    Sambrook PN
    N Engl J Med; 2007 Nov; 357(20):2084-6. PubMed ID: 18003966
    [No Abstract]   [Full Text] [Related]  

  • 70. Discovery and development of antidepressants: a perspective from a pharmaceutical discovery company.
    Scolnick EM
    Biol Psychiatry; 2002 Aug; 52(3):154-6. PubMed ID: 12182921
    [No Abstract]   [Full Text] [Related]  

  • 71. Intragastric alendronate therapy in two infants with vitamin D intoxication: a new method.
    Doneray H; Ozkan B; Caner I; Ozkan A; Karakelleoglu C
    Clin Toxicol (Phila); 2008 Apr; 46(4):300-2. PubMed ID: 18363123
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Denosumab in postmenopausal women with low bone mineral density.
    Rifkin WD
    N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16742010
    [No Abstract]   [Full Text] [Related]  

  • 73. Osteonecrosis of femoral head treated with alendronate in a 14-year-old boy: a case report.
    Cheon SH; Oh CW; Park SK
    J Pediatr Orthop B; 2012 May; 21(3):260-3. PubMed ID: 21811181
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing.
    Colón-Emeric CS
    JAMA; 2006 Dec; 296(24):2968-9. PubMed ID: 17190899
    [No Abstract]   [Full Text] [Related]  

  • 75. Interaction between IGF-1, inflammation, and neuropathy in the pathogenesis of acute charcot neuroarthropathy: lessons from alendronate therapy and future perspectives of medical therapy.
    Pitocco D; Collina MC; Musella T; Ruotolo V; Caputo S; Manto A; Caradonna P; Galli M; Mancini L; Ghirlanda G
    Horm Metab Res; 2008 Mar; 40(3):163-4. PubMed ID: 18256973
    [No Abstract]   [Full Text] [Related]  

  • 76. [Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].
    Yamada S; Inaba M; Nishizawa Y
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():348-51. PubMed ID: 18161129
    [No Abstract]   [Full Text] [Related]  

  • 77. Estriol, conjugated equine estrogens, and alendronate therapy for osteoporosis.
    Terauchi M; Obayashi S; Aso T
    Int J Gynaecol Obstet; 2006 Feb; 92(2):141-2. PubMed ID: 16305796
    [No Abstract]   [Full Text] [Related]  

  • 78. Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program.
    Das S; Lo AW
    Contemp Clin Trials; 2017 Nov; 62():168-174. PubMed ID: 28899813
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Unfavourable results and drug company trials.
    Bardhan KD
    Lancet; 1987 Jun; 1(8548):1492. PubMed ID: 2885481
    [No Abstract]   [Full Text] [Related]  

  • 80. Heavy drugs draw heavy interest from pharma backers.
    Katsnelson A
    Nat Med; 2013 Jun; 19(6):656. PubMed ID: 23744136
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.